medigraphic.com
Colegio de Medicina Interna de México.

2007, Number 2

<< Back Next >>

Med Int Mex 2007; 23 (2)

Clinical applications of tioctic acid (α-lipoic acid) in patients with symptomatic diabetic neuropathy: a review

Cantú BC, Baizábal CF, Aldrete VJ, Chávez GE

Language: Spanish
References: 40
Page: 151-158
PDF size: 139.37 Kb.


ABSTRACT

Diabetes mellitus is the main cause of neuropathy worldwide, being common place for patients to suffer from it at some stage of the disease. Tioctic acid o α-lipoic acid and its related metabolites, due to their antioxidant and chelating properties, have proved an effective therapy for dealing with this complication. In addition, tioctic acid is also helpful in treating chemotherapy-associated neuropathies due to doxetacel or cisplatin.


REFERENCES

  1. Humphey LL, Ballard DJ, Frohnert PP. Chronic renal failure in non-insulin-dependent diabetes mellitus. Ann Inter Med 1989;111:788-96.

  2. Clements R, Bell D. Complications of diabetes. Prevalence detection, current treatment an prognosis. Am J Med 1985;79(5A):2-7.

  3. Rull A. The impact of diabetes mellitus on public health in Mexico. Current Science 1995:64-74.

  4. Greene D, Lattimer S, Sima, A. Sorbitol, phosphoinositides, and sodium-potasium ATPase in the pathogenesis of diabetic complications. N Engl J Medicine 1987;316(10):599- 605.

  5. Ziegler D. Diagnosis, staging and epidemiology of diabetic peripheral neuropathy. Diabetes Nutr Metab 1994;7:342-48.

  6. Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic ulcer. Diabet Med 1996;13:967-72.

  7. Zochodne D. Diabetic neuropathies: features and mechanisms. Brain Pathol 1999;9:369-91.

  8. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003;52:165-71.

  9. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992;15:1902-25.

  10. Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 1989;31:355-438.

  11. Cameron NE, Cotter MA. Effects of evening primrose oil treatment on sciatic nerve blood flow and endoneurial oxygen tension in streptozotocin-diabetic rats. Acta Diabetol 1994;31:220-25.

  12. Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;26:258-67.

  13. Rull JA y colaboradores. Cambios histológicos y funcionales. En: Consenso sobre neuropatía diabética. Grupo Nacional de Consenso en Diabetes. Fundación Mexicana para la Salud. México, 1996.

  14. Otero-Siliceo E, Ruano-Calderón L. Neuropatía diabética: ¿una enfermedad vascular? Rev Neurol 2003;37(7): 658-61.

  15. Schultz J, Harris AK, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Card Diabetology 2005;4:5.

  16. Martínez-Conde A, Paredes FC, Zacarías CR. Neuropatía diabética. Rev Hosp Gral M Gea González 2002;5(1 y 2): 7-23.

  17. Aldrete-Velasco J y col. Correlación entre nefropatía, neuropatía y retinopatía en pacientes con diabetes mellitus no insulinodependiente. Rev Asoc Med Intern de México 1995;11(3):109-14.

  18. Aldrete VJ, Morales SJ, Villicaña MH, Aldrete JA y col. Eficacia clínica y neurofisiológica del tolrestato en pacientes con neuropatía diabética avanzada. Rev Med Int Méx 1995;11(4):160-7.

  19. Effect of intensive treatment on nerve conduction in the Diabetes Control and Complication Trial. Ann Neurol 1995;38:869-80

  20. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995;122:561-66.

  21. Snell EE, Strong FM, Peterson WH. Growth factors for bacteria. Fractionation and properties of an accessory factor for lactic acid bacteria. Biochem J 1937;31:1789.

  22. Reed LJ, DeBusk BG, Gunsalus IC, Hornberger CS. Crystalline α-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science 1951;114:93-103.

  23. Reed LJ. The chemistry and function of lipoic acids. Adv Enzymol 1957;18:319-47.

  24. Carreau JP. Biosynthesis of lipoic acid via unsaturated fatty acids. Meth Enzymol 1979;62:152-58.

  25. Jordan SW, Cronan JE. Biosynthesis of lipoic acid and posttranslational modification with lipoic acid in Escherichia coli. Methods Enzymol 1997;279:176.

  26. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmac 1997;29(3):315-31.

  27. Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther 1998;36:625.

  28. Spence JT, McCormick DB. Lipoic acid metabolism in the rat. Arch Biochem Biphys 1976;174:13.

  29. Biewenga G, Haenen GR, Bast A. The role of lipoic acid metabolism in the treatment of diabetic polyneuropathy. Drug Metab Rev 1997;29:1025.

  30. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18:1160-67.

  31. Ziegler D, Hanefeld MH, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999;22:1296-1301.

  32. Ametov S, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with [alpha]-lipoic acid: The SYDNEY Trial. Diabetes Care 2003;26:770-76.

  33. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant [alpha]-lipoic acid: a meta-analysis. Diabetic Medicine 2004;21:114-21.

  34. Ziegler D, Schatz H, Conrad F, Gries FA, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997;20:369-73.

  35. Strodter D, Lehmann E, Lehmann U, Tritschler HJ, et al. The influence of thioctic acid on metabolism and function of the diabetic heart. Diabetes Res Clin Pract 1995;29:19-26.

  36. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994;10:339-83.

  37. Gedlicka GV, Kornek K, Schmid WS. Amelioration of docetaxel/ cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 2003;14:339-40.

  38. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11:509-13.

  39. Culy CR, Clemett D, Wiseman LR. Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.

  40. Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359-61.




2020     |     www.medigraphic.com